“…IAIPs are endogenously present in the circulation and in many cell types [ 9 , 10 , 11 , 12 , 13 ], where they act to inhibit destructive proteases, decrease the quantity of damaging cytokines, and alter immune cell responses [ 14 ]. Treatment of neonatal rats with exogenous human IAIPs (hIAIPs) after exposure to HI has been shown to decrease infarct volumes in the brain, preserve neurons and oligodendrocytes, decrease the number of microglia, attenuate peripheral immune responses, and improve behavioral outcomes [ 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. Therapeutic hIAIPs are isolated and purified from human plasma, which is a costly process and subject to human plasma availability.…”